Doxorubicin-Transdrug in Advanced HepatoCellular Carcinoma A Randomized, Multicenter Phase 2-3 Study.
Latest Information Update: 11 Aug 2017
At a glance
- Drugs Doxorubicin (Primary) ; Antineoplastics
- Indications Liver cancer
- Focus Therapeutic Use
- Acronyms DOTAHCC1
- Sponsors BioAlliance Pharma
- 11 Aug 2017 This trial has been Discontinued in Belgium, according to European Clinical Trials Database.
- 11 Aug 2014 Status changed from suspended to completed as reported by European Clinical Trials Database record.
- 06 Sep 2011 Preliminary results of 28 evaluable patients (of a planned 50) were presented at the annual congress of the International Liver Cancer Association, as reported in a BioAlliance Pharma media release.